Gregory Klein Selected Research

Amyloid (Amyloid Fibrils)

11/2023	Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
10/2023	Validation of 3- and 5-point severity scales to assess ARIA-E.
1/2023	Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.
1/2023	The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.
1/2023	Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
1/2023	Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
11/2022	Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.
11/2022	Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
1/2022	Comparing ARIA-E severity scales and effects of treatment management thresholds.
1/2022	In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregory Klein Research Topics

Disease

21	Alzheimer Disease (Alzheimer's Disease) 11/2023 - 01/2016
7	Dementia (Dementias) 01/2023 - 01/2019
6	Cognitive Dysfunction 01/2023 - 01/2021
4	Edema (Dropsy) 11/2023 - 01/2022
2	Amyloid Plaque 11/2023 - 11/2022
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 01/2021
2	Disease Progression 11/2022 - 09/2015
1	Drug-Related Side Effects and Adverse Reactions 10/2023
1	Atrophy 01/2023
1	Prodromal Symptoms 01/2021
1	Primary Progressive Aphasia 01/2020

Drug/Important Bio-Agent (IBA)

17	Amyloid (Amyloid Fibrils)IBA 11/2023 - 09/2015
8	Biomarkers (Surrogate Marker)IBA 09/2023 - 01/2019
7	gantenerumabIBA 11/2023 - 12/2017
5	Monoclonal AntibodiesIBA 11/2023 - 01/2022
4	Amyloid beta-PeptidesIBA 11/2023 - 01/2022
3	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2021 - 01/2020
2	Apolipoproteins E (ApoE)IBA 01/2023 - 01/2021
1	Immunoglobulin G (IgG)IBA 11/2023
1	AntibodiesIBA 10/2023
1	prothrombin complex concentrates (PPSB)IBA 09/2023
1	ApolipoproteinsIBA 01/2023
1	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2023
1	solanezumabIBA 11/2022
1	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA 01/2022
1	FluorineIBA 01/2021
1	florbetapirIBA 12/2019

Therapy/Procedure

2	Therapeutics 01/2023 - 01/2022